Erschienen in:
Open Access
19.08.2023 | Correction
Correction to: Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation
verfasst von:
Andrea Chiricozzi, Michela Ortoncelli, Donatella Schena, Niccolò Gori, Silvia Mariel Ferrucci, Graziella Babino, Maddalena Napolitano, Maria Concetta Fargnoli, Luca Stingeni, Mariateresa Rossi, Marco Romanelli, Riccardo Balestri, Michele Pellegrino, Aurora Parodi, Alberto Maria Bertoldi, Giovanni Palazzo, Flaminia Antonelli, Annalisa Pitino, Giovanni Tripepi, Gabriella Fabbrocini, Anna Balato, Angelo Valerio Marzano, Giampiero Girolomoni, Simone Ribero, Ketty Peris
Erschienen in:
American Journal of Clinical Dermatology
|
Ausgabe 6/2023
In the Acknowledgements section of this article the last sentence, which previously read:
“Medical writing was funded through a donation by AbbVie Srl.”
should have read:
“Medical writing was funded by SIDeMaST.”
The original article has been corrected.
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by-nc/4.0/.